abstract |
The present invention relates to the field of disorders of the peripheral or central nervous system, in particular Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the present invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting. |